UK's NHS Prescribes Weight-Loss Drug Wegovy Less Than Expected Due To Service Shortages
Portfolio Pulse from Vandana Singh
The UK's NHS has prescribed Novo Nordisk's weight-loss drug Wegovy far less than expected due to a shortage of weight management clinics. Despite high demand and regulatory approval for reducing heart risks, the drug's international supply is limited. The NHS has prioritized supplies of Ozempic, another Novo Nordisk drug for type-2 diabetes, over Wegovy. The shortfall is also due to a lack of specialist NHS weight-loss services.
July 24, 2024 | 6:58 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Novo Nordisk's weight-loss drug Wegovy is being prescribed less than expected by the NHS due to a shortage of weight management clinics and international supply constraints. Despite high demand and regulatory approval, the NHS is prioritizing Ozempic for type-2 diabetes over Wegovy.
The lower-than-expected prescriptions of Wegovy by the NHS, coupled with international supply constraints and prioritization of Ozempic, are likely to negatively impact Novo Nordisk's short-term revenues and stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100